← Back to Clinical Trials
Recruiting NCT06609603

NCT06609603 Clinical Study to Evaluate the Body Fat Reducing Effects of Heat-Treated Green Tea Extract Complex

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06609603
Status Recruiting
Phase
Sponsor Amorepacific Corporation
Condition Body Fat
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2023-11-17
Primary Completion 2025-05-30

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age 64 Years
Study Type INTERVENTIONAL
Interventions
HTGT compoundPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2023-11-17 with a primary completion date of 2025-05-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical study was designed to evaluate the efficacy and safety of body fat reduction in obese adults by treatment of heat-treated green tea extract complex

Eligibility Criteria

* lt;Inclusion Criteria\> * Males and females aged between 19 \~ 64 years * BMI 25.0 \~ 34.9 kg/m\^2 * Waist circumferebce: 90cm or more for men, 85cm or more for women * Subjects who have fully understand the information provided about the study and voluntarily decided to participate * lt;Exclusion Criteria\> * Participants whose weight changed by more than 10% within the 3 months prior to visit 1 * Individuals participated in a commercial weight loss program within 3 months prior to Visit 1 * Participants who have undergone surgical procedures within 3 years * Participants who have taken obesity treatment medications within the last 3 months * Individuals who have taken medications affecting weight or dietary supplements for weight control within the last month * Subjects with uncontrolled hypertension * Subjects diagnosed with diabetes * TSH \<0.1 uIU/ml or \>10 uIU/ml * Creatinine \>1.5mg/dL * AST or ALT \> three times the upper normal limit

Contact & Investigator

Central Contact

Jonghee Sohn

✉ sohnjh@amorepacific.com

📞 800-555-5555

Principal Investigator

Sang-Wook Song, M.D./Ph.D

PRINCIPAL INVESTIGATOR

Catholic University St. Vincent Hospital

Frequently Asked Questions

Who can join the NCT06609603 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, up to 64 Years, studying Body Fat. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06609603 currently recruiting?

Yes, NCT06609603 is actively recruiting participants. Contact the research team at sohnjh@amorepacific.com for enrollment information.

Where is the NCT06609603 trial being conducted?

This trial is being conducted at Suwon, South Korea.

Who is sponsoring the NCT06609603 clinical trial?

NCT06609603 is sponsored by Amorepacific Corporation. The principal investigator is Sang-Wook Song, M.D./Ph.D at Catholic University St. Vincent Hospital. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology